- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04659707
Hyperpolarized 129Xe MRI of Survivors of COVID-19
Evaluating Lung Structure and Function in Survivors of COVID-19 Using Hyperpolarized 129Xe MRI
Study Overview
Detailed Description
COVID-19, the disease at the heart of the current global pandemic, is characterized by fevers, cough, sore throat, malaise, and myalgias, with 98% of patients experiencing some pulmonary involvement. In those infected with the causative virus, SARS-CoV-2, the severity of symptoms, as well as their duration, is widely variable. There is strong evidence from computed tomography (CT) images of patients with severe COVID-19 that pulmonary abnormalities and lung damage caused by infection may have long-term consequences for survivors. Furthermore, many patients with mild or moderate experience symptoms such as fatigue and dyspnea long (>60 days) after initial symptom onset, but there are currently no clinical predictors of which patients are at greatest risk for long-term health effects. As such, sensitive and specific predictors or biomarkers that can evaluate quality-of-life, risk of infection exacerbation, and long-term outcomes are critically needed.
Pulmonary imaging using hyperpolarized (HP) 129Xe magnetic resonance imaging (MRI) provides a means to detect abnormalities in the pulmonary small airways, vasculature, and parenchyma by quantifying pulmonary ventilation, gas diffusion, and regional gas exchange. HP 129Xe MRI is fast (<16s), non-invasive, and radiation free, making it a safe and effective method for characterizing lung function, even in individuals with lung disease. In this pilot study, we will use HP 129Xe to evaluate pulmonary structure and function in COVID-19 patients using the following specific aims:
Aim 1. Detect regional pulmonary function abnormalities in recovering COVID-19 patients using hyperpolarized 129Xe MRI. The hypothesis is that ventilation and gas exchange defects will be present in recovering COVID-19 patients, and further that the extent of impairment will correlate with disease severity.
Aim 2. Determine risk factors for long term outcomes using hyperpolarized 129Xe MRI and clinical biomarkers. The hypothesis is that HP 129Xe MRI biomarkers will predict long-term lung function impairment brought on by COVID-19.
These aims will be tested by performing HP 129Xe MRI in patients recovering from mild, moderate, or severe COVID-19. By coming to a fuller understanding of the long-term impairment of pulmonary function, future treatment can be optimized to minimize severe disease and health care utilization.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Peter J Niedbalski, PhD
- Phone Number: 9135882271
- Email: pniedbalski@kumc.edu
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Recruiting
- University of Kansas Medical Center
-
Contact:
- Peter J Niedbalski, PhD
- Phone Number: 913-588-2271
- Email: pniedbalski@kumc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Oxygenation saturation of ≥88% at rest by study staff within 48 hours prior to study entry.
- The participant has a previous diagnosis of COVID-19 confirmed by COVID-19 PCR or antibody testing and is being seen for outpatient follow-up.
- Subject is at least 10 days post-symptom-onset and do not have a fever (<99.5°).
- Ability to read and understand English or Spanish
Exclusion Criteria:
- Subject is less than 18 years old
- MRI is contraindicated based on responses to MRI screening questionnaire
- Subject is pregnant or lactating
- Subject does not fit into 129Xe vest coil used for MRI
- Subject cannot hold his/her breath for 15-16 seconds
- Subject deemed unlikely to be able to comply with instructions during imaging
- Oxygen saturation <88% on room air or with supplemental oxygen
- Cognitive deficits that preclude ability to provide consent
- Institutionalization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: COVID-19 Survivors
Subjects recovering from COVID-19 disease will be imaged using hyperpolarized 129Xe MRI.
|
Subjects will inhale up to 4 doses of hyperpolarized Xenon gas in order to image pulmonary function.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ventilation Defect Percentage
Time Frame: Baseline
|
VDP at Baseline
|
Baseline
|
Ventilation Defect Percentage
Time Frame: 6-months
|
VDP at 6 months
|
6-months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00146646
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Hyperpolarized Xe129
-
University of Kansas Medical CenterScleroderma FoundationRecruiting
-
Children's Hospital Medical Center, CincinnatiRecruiting
-
Bastiaan DriehuysRegeneron PharmaceuticalsWithdrawnPulmonary Artery Hypertension
-
Mario Castro, MD, MPHRecruitingAsthma | Cystic Fibrosis | Pulmonary Hypertension | Interstitial Lung Disease | COPD | Pulmonary Infection | Other Lung DiseaseUnited States
-
University of Kansas Medical CenterBoehringer Ingelheim; Duke University; Children's Hospital Medical Center, CincinnatiWithdrawnIdiopathic Pulmonary Fibrosis | Hypersensitivity Pneumonitis
-
Bastiaan DriehuysNational Institutes of Health (NIH)RecruitingPolycythemia | Anemia | Interstitial Lung Disease | Dyspnea | Chronic Thromboembolic Pulmonary Hypertension | Acute Pulmonary EmbolismUnited States
-
University of Kansas Medical CenterJohns Hopkins University; M.D. Anderson Cancer Center; Baylor College of Medicine and other collaboratorsNot yet recruiting
-
University of Kansas Medical CenterAmerican Heart AssociationRecruitingPulmonary Arterial HypertensionUnited States
-
Chang Gung Memorial HospitalMinistry of Science and Technology, TaiwanRecruiting
-
Bastiaan DriehuysNational Heart, Lung, and Blood Institute (NHLBI); University of Iowa; Children... and other collaboratorsRecruitingInterstitial Lung DiseasesUnited States